Time	time	O	O	O	O
dependence	dependence	O	O	O	O
of	of	O	O	O	O
plasma	plasma	O	O	O	O
malondialdehyde	malondialdehyde	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
oxypurines	oxypurines	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
nucleosides	nucleosides	O	O	OTHERS	I
during	during	O	O	O	O
incomplete	incomplete	O	O	O	O
cerebral	cerebral	O	O	OTHERS	I
ischemia	ischemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
rat	rat	O	O	O	O
.	.	O	O	O	O

Incomplete	incomplete	O	O	O	O
cerebral	cerebral	O	O	OTHERS	I
ischemia	ischemia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
30	30	O	O	O	O
min	min	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
induced	induced	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
rat	rat	O	O	O	O
by	by	O	O	O	O
bilaterally	bilaterally	O	O	O	O
clamping	clamping	O	O	O	O
the	the	O	O	O	O
common	common	O	O	O	O
carotid	carotid	O	O	O	O
arteries	arteries	O	O	O	O
.	.	O	O	O	O

Peripheral	peripheral	O	O	O	O
venous	venous	O	O	O	O
blood	blood	O	O	O	O
samples	samples	O	O	O	O
were	were	O	O	O	O
withdrawn	withdrawn	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
femoral	femoral	O	O	O	O
vein	vein	O	O	O	O
four	four	O	O	O	O
times	times	O	O	O	O
(	(	O	O	O	O
once	once	O	O	O	O
every	every	O	O	O	O
5	5	O	O	O	O
min	min	O	O	O	O
)	)	O	O	O	O
before	before	O	O	O	O
ischemia	ischemia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
0	0	O	O	O	O
time	time	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
5	5	O	O	O	O
,	,	O	O	O	O
15	15	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
30	30	O	O	O	O
min	min	O	O	O	O
after	after	O	O	O	O
ischemia	ischemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Plasma	plasma	O	O	O	O
extracts	extracts	O	O	O	O
were	were	O	O	O	O
analyzed	analyzed	O	O	O	O
by	by	O	O	O	O
a	a	O	O	O	O
highly	highly	O	O	O	O
sensitive	sensitive	O	O	O	O
high-performance	high-performance	O	O	O	O
liquid	liquid	O	O	O	O
chromatographic	chromatographic	O	O	O	O
method	method	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
direct	direct	O	O	O	O
determination	determination	O	O	O	O
of	of	O	O	O	O
malondialdehyde	malondialdehyde	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
oxypurines	oxypurines	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
nucleosides	nucleosides	O	O	OTHERS	I
.	.	O	O	O	O

During	during	O	O	O	O
ischemia	ischemia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
time-dependent	time-dependent	O	O	O	O
increase	increase	O	O	O	O
of	of	O	O	O	O
plasma	plasma	O	O	O	O
oxypurines	oxypurines	O	O	OTHERS	I
and	and	O	O	O	O
nucleosides	nucleosides	O	O	OTHERS	I
was	was	O	O	O	O
observed	observed	O	O	O	O
.	.	O	O	O	O

Plasma	plasma	O	O	O	O
malondialdehyde	malondialdehyde	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
was	was	O	O	O	O
present	present	O	O	O	O
in	in	O	O	O	O
minimal	minimal	O	O	O	O
amount	amount	O	O	O	O
at	at	O	O	O	O
zero	zero	O	O	O	O
time	time	O	O	O	O
(	(	O	O	O	O
0.058	0.058	O	O	O	O
mumol/liter	mumol/liter	O	O	O	O
plasma	plasma	O	O	O	O
;	;	O	O	O	O
SD	sd	O	O	OTHERS	I
0.015	0.015	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
increased	increased	O	O	O	O
after	after	O	O	O	O
5	5	O	O	O	O
min	min	O	O	O	O
of	of	O	O	O	O
ischemia	ischemia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
resulting	resulting	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
fivefold	fivefold	O	O	O	O
increase	increase	O	O	O	O
after	after	O	O	O	O
30	30	O	O	O	O
min	min	O	O	O	O
of	of	O	O	O	O
carotid	carotid	O	O	O	O
occlusion	occlusion	O	O	O	O
(	(	O	O	O	O
0.298	0.298	O	O	O	O
mumol/liter	mumol/liter	O	O	O	O
plasma	plasma	O	O	O	O
;	;	O	O	O	O
SD	sd	O	O	OTHERS	I
0.078	0.078	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Increased	increased	O	O	O	O
plasma	plasma	O	O	O	O
malondialdehyde	malondialdehyde	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
also	also	O	O	O	O
recorded	recorded	O	O	O	O
in	in	O	O	O	O
two	two	O	O	O	O
other	other	O	O	O	O
groups	groups	O	O	O	O
of	of	O	O	O	O
animals	animals	O	O	O	O
subjected	subjected	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
same	same	O	O	O	O
experimental	experimental	O	O	O	O
model	model	O	O	O	O
,	,	O	O	O	O
one	one	O	O	O	O
receiving	receiving	O	O	O	O
20	20	O	O	O	O
mg/kg	mg/kg	O	O	O	O
b.w	b.w	O	O	O	O
.	.	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
cyclooxygenase	cyclooxygenase	O	O	O	O
inhibitor	inhibitor	O	O	O	O
acetylsalicylate	acetylsalicylate	O	O	OTHERS	I
intravenously	intravenously	O	O	O	O
immediately	immediately	O	O	O	O
before	before	O	O	O	O
ischemia	ischemia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
receiving	receiving	O	O	O	O
650	650	O	O	O	O
micrograms/kg	micrograms/kg	O	O	O	O
b.w	b.w	O	O	O	O
.	.	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
hypotensive	hypotensive	O	DISEASE	OTHERS	I
drug	drug	O	O	O	O
nitroprusside	nitroprusside	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
a	a	O	O	O	O
flow	flow	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
103	103	O	O	O	O
microliters/min	microliters/min	O	O	O	O
intravenously	intravenously	O	O	O	O
during	during	O	O	O	O
ischemia	ischemia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
although	although	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
latter	latter	O	O	O	O
group	group	O	O	O	O
malondialdehyde	malondialdehyde	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
significantly	significantly	O	O	O	O
higher	higher	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
present	present	O	O	O	O
data	data	O	O	O	O
indicate	indicate	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
determination	determination	O	O	O	O
of	of	O	O	O	O
malondialdehyde	malondialdehyde	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
oxypurines	oxypurines	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
nucleosides	nucleosides	O	O	OTHERS	I
in	in	O	O	O	O
peripheral	peripheral	O	O	O	O
blood	blood	O	O	O	O
,	,	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
used	used	O	O	O	O
to	to	O	O	O	O
monitor	monitor	O	O	O	O
the	the	O	O	O	O
metabolic	metabolic	O	O	O	O
alterations	alterations	O	O	O	O
of	of	O	O	O	O
tissues	tissues	O	O	O	O
occurring	occurring	O	O	O	O
during	during	O	O	O	O
ischemic	ischemic	O	O	OTHERS	I
phenomena.(ABSTRACT	phenomena.(abstract	O	O	O	O
TRUNCATED	truncated	O	O	O	O
AT	at	O	O	O	O
250	250	O	O	O	O
WORDS	words	O	O	O	O
)	)	O	O	O	O

